Attorney's Docket No.: 07039-501US1 / MM



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peter J. Wettstein et al.

Art Unit : 1644

Serial No.: 10/587,925

Examiner: Unknown

Filed

: August 2, 2006

Title

: COMPLEXED POLYPEPTIDE AND ADJUVANT FOR IMPROVED

VACCINES

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Copies of communications from a foreign patent office in a counterpart application are also enclosed.

This statement is being filed within three months of the filing date of the application. No fees are believed to be due. If this is incorrect, please apply any necessary charges, or any credits, to Deposit Account No. 06-1050, referencing Attorney Docket No. 07039-501US1.

Respectfully submitted,

Allyson R. Hatton.

Reg. No. 54,154

Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110

Telephone: (617) 542-5070 Facsimile: (617) 542-8906

21406975.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.Q. Bax 1450, Alexandria, VA 22313-1450.

Signature

Typed or Printed Name of Person Signing Certificate

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-501US1	Application No. 10/587,925	
by Ap	closure Statement P E	Applicant Peter J. Wettstein et al.		
(Use several sh	neets if necessary)	Filing Date	Group Art Unit	
(37 CFR §1.98(b))	OCT 0 & 2006	August 2, 2006	1644	
	\ \$			

Foreign Patent Document Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or			Translation	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AA	WO 02/32451	04/25/2002	WIPO				
	AB	WO 03/082327	10/09/2003	WIPO				
	AC	WO 05/076975	08/25/2005	WIPO				
	AD							
	AE							

	Other	Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID			
	AF	Buschle et al., "Transloading of tumor antigen-derived peptides into antigen-presenting cells," Proc. Natl. Acad. Sci. USA, 94:3256-3261, 1997.		
	AG	Davis et al., "CpG DNA Is a Potent Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B surface Antigen" J. Immunol. 160:870-876, 1998.		
	AH	Dyer et al., "The quiet revolution: A new synthesis of biological knowledge.," Journal of Biological Education 5:15-24, 1971.		
•	AI	Engelhard et al., "Influenza A-Specific, HLA-A2.1 – Restricted Cytotoxic T Lymphocytes from HLA-A2.1 Transgenic Mice Recognize Fragments of the MI Protein" J. Immunol, 146:1226-1232, Feb. 1991.		
	AJ	Greenfield et al., "An H-YD ^b epitope is enclosed by a novel mouse Y chromosome gene" Nature Genetics 14:474-478, 1996.		
	AK	Heit et al., "Cutting Edge: Toll-Like Receptor 9 Expression is Not Required for CpG DNA-Aided Cross-Presentation of DNA-Conjugated Antigens but Essential for Cross-Priming of CD8 T Cells," J. Immunol. 170:2802-2805, 2003.		
	AL	King and Jukes, "Non-Darwinian Evolution," Science, 164:788-798, 1969.		
	AM	King et al., "Deletion Mapping by Immunoselection against the H-Y Histocompatibility Antigen Further Resolves the Sxr ^a Region of the Mouse Y Chromosome and Reveals Complexity of the Hya Locus," Genomics 24:159-168, 1994.		
	AN	Krieg, "CPG Motifs in Bacterial DNA and Their Immune Effects," Annu. Rev. Immunol., 20:709-760, 2002.		
-	AO	Le et al., "Cytotoxic T Cell Responses in HLA-A2.1 Transgenic Mice Recognition of HLA Alloantigens and Utilization of HLA-A2.1 as a Restriction Element," J. Immunol., 142:1366-1371 1989.		
	AP	Lingnau et al., "Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (GpG-ODN) for enhanced and prolonged immune responses and prevent the CpG-ODN-induced systemic release of pro-inflammatory cytokines," <i>Vaccine</i> 20:3498-3508, 2002.		
	AQ	Lu et al., "TAP-Independent Presentation of CTL Epitopes by Trojan Antigens," J. Immunol. 166:7063-7071, 2001.		

Examiner Signature	Date Considered			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-501US1	Application No. 10/587,925	
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Peter J. Wettstein et al.		
		Filing Date August 2, 2006	Group Art Unit 1644	

	Other Documents (include Author, Title, Date, and Place of Publication)				
	Examiner	Desig.			
	Initial	ID	Document		
		AR	Lührs et al. "Induction of Specific Immune Responses by Polycation-Based Vaccines," J. Immunol. 169:5217-5226, 2002.		
10	PEIN	AS	Malarkannan et al., "The Molecular and Functional Characterization of a Dominant Minor H Antigen, H60," J. Immunol., 161:3501-3509, 1998.		
	0 & 2006 J	AT	Mattner et al., "Vaccination with Poly-L-Arginine As Immunostimulant for Peptide Vaccines: Induction of Potent and Long-Lasting T-Cell Responses against Cancer Antigens," Cancer Res., 62:1477-1480, 2002		
TENTET	AU Maurer et al., "CpG-DNA Aided Cross-Presentation of Soluble Antigens by Dendritic Cel Immunol. 32:2356-2364, 2002				
		AV	Schirmbeck et al., "Antigenic Epitopes Fused to Cationic Peptide Bound to Oligonucleotides Facilitate Toll-Like Receptor 9-Dependent, but CD4 ⁺ T Cell Help-Independent, Primint of CD8 ⁺ T Cells," J. Immunol. 171:5198-5207, 2003.		
	AW Schmidt et al., "Cell-free Tumor Antigen Peptide-Based Cancer Vaccines," Proc. Natl. USA, 94:3262-3267, 1997.		Schmidt et al., "Cell-free Tumor Antigen Peptide-Based Cancer Vaccines," Proc. Natl. Acad. Sci. USA, 94:3262-3267, 1997.		
		AX	Vivès et al., "A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus," J. of Biological Chem., 272:16010-16017, 1997.		
	AY Zwaveling et al., "Established Human Papillomavirus Type 16-Expressing Tumors are Effect Eradicated following Vaccination with Long Peptides," J. of Immunol., 169:350-358, 2002.				

Examiner Signature	Date Considered				
	· ·				
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					